In agreement with this, in vitro and xenotransplantation studies with glioma cell lines have indicated that CD133-positive GSCs are particularly sensitive to γ-secretase inhibitors (GSI) or NOTCH1/2 knockdown compared to CD133-negative glioma cells [108,109]. This evidence concerns the gene NOTCH1 and central nervous system cancer.